Grant ID CP120036
Awarded On March 29, 2012
Title TexCITE (Texas Cancer ImmunoTherapy Enterprise): Focused development of innovative cell therapies for cancer
Program Product Development Research
Award Mechanism Company Relocation
Institution/Organization Cell Medica
Principal Investigator/Program Director Gregg Sando
Cancer Sites Lymphoma, Other
Contracted Amount $15,571,303
Lay Summary

Cell Medica is a leader in the development of cellular immunotherapy for cancer applications. Cell Medica is applying for a Relocation Award to achieve FDA approval for two cell therapies: Cytorex EBV for the treatment of cancers associated with the Epstein Barr virus (EBV) and Cytovir CMV for cytomegalovirus (CMV) infections in patients following bone marrow transplant.

Support for Cytorex EBV fits with CPRIT’s mission to foster new therapies for cancer treatment. 1) Cellular immunotherapies provide powerful tools for the treatment of cancer and Cytorex EBV is a breakthrough for patients with EBV-associated cancers. 2) The safety of Cytorex EBV will improve long-term outcomes allowing treat...

Read More